Seven Year Survival After Multiple Recurrences and Repeated Metastasectomies with Targeted Therapies for Renal Cell Carcinoma
Erkan Arpaci *
Department of Medical Oncology, Bulent Ecevit University, Faculty of Medicine, Zonguldak, Turkey.
Selcuk Ergen
Department of Medical Oncology, Bulent Ecevit University, Faculty of Medicine, Zonguldak, Turkey.
Yasemin Bakkal Temi
Department of Medical Oncology, Bulent Ecevit University, Faculty of Medicine, Zonguldak, Turkey.
Burak Bahadir
Department of Pathology, Bulent Ecevit University, Faculty of Medicine, Zonguldak, Turkey.
Huseyin Engin
Department of Medical Oncology, Bulent Ecevit University, Faculty of Medicine, Zonguldak, Turkey.
*Author to whom correspondence should be addressed.
Abstract
Background: In spite of resistance and limited response to chemotherapy, radiotherapy and immunotherapy, recent advances led to several targeted agents that showed the prolongation of progressive free survival. Due to these facts, surgical resection of multiple recurrences may be worthwhile in selected patients with kidney cancer.
Case Report: We report a case of a 47-year-old man who underwent nephrectomy for T4N0 RCC, clear cell type, Fuhrman grade 2/4 in 2007. The patient afterward had multiple tumor recurrences. He underwent four metastasectomies, including liver, skin, rectum and scalp. And he received immunotherapy and multiple lines biological targeted treatments. He remains stable for 7 years after initial diagnosis.
Conclusion: In patients with metastatic RCC, recurrent resections can be achieved safely and giving biological drugs may prolong survival. Close follow-up is important for the early detection of recurrence and complete resection of metastases can improve the outcomes of patients.
Keywords: Renal cell carcinoma, metastasis, targeted therapies.